The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing Policies
暂无分享,去创建一个
J. Fonseca | A. Todo-Bom | A. Sá-Sousa | A. Pereira | Ana Ferreira | A. Arrobas | A. Mendes | M. Drummond | W. Videira | T. Costa | Pedro Farinha | J. Soares | P. Rocha | A. Sokolova | A. Costa | B. Fernandes | C. Chaves Loureiro | C. Longo | C. Pardal | C. Costa | C. Cruz | C. Loureiro | C. Lopes | D. Mesquita | E. Faria | E. Magalhães | F. Menezes | F. Todo-Bom | F. Carvalho | F. Regateiro | H. Falcão | I. Fernandes | J. Gaspar-Marques | Jorge Viaña | J. Ferreira | J. M. Silva | L. Simão | L. Almeida | L. Fernandes | L. Ferreira | M. van Zeller | M. Quaresma | M. Castanho | N. André | N. Cortesão | P. Leiria-Pinto | P. Pinto | P. Rosa | P. Carreiro-Martins | R. Gerardo | Rui Silva | Susana Lucas | T. Almeida | T. Calvo | Nuno Cortesão | P. Carreiro‐Martins | Filipa Todo-Bom | António Costa | Paula Rosa
[1] D. Hunter,et al. Qualitative Research: Consensus methods for medical and health services research , 1995 .
[2] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[3] Sally Green,et al. Clinical practice guidelines: a guide to better practice, not a recipe for uniformity. , 2003, The Australian journal of physiotherapy.
[4] A. Gulsvik,et al. The socio‐economic burden of asthma is substantial in Europe , 2007, Allergy.
[5] Nancy A Dreyer,et al. Registries for robust evidence. , 2009, JAMA.
[6] C. Brightling,et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry , 2010, Thorax.
[7] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[8] J. Bousquet,et al. Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time , 2012, Clinical and Translational Allergy.
[9] R. Buhl,et al. Das Register „Schweres Asthma“ , 2012, Pneumologie.
[10] C. Brightling,et al. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry , 2012, Thorax.
[11] S. Korn,et al. [The German severe asthma registry]. , 2012, Pneumologie.
[12] Tiago Jacinto,et al. Prevalence of asthma in Portugal - The Portuguese National Asthma Survey , 2012, Clinical and Translational Allergy.
[13] K. Bergmann,et al. The German severe asthma register , 2012 .
[14] J. F. Medina,et al. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.
[15] Dear Mr Sotiropoulos. ARTICLE 29 Data Protection Working Party , 2013 .
[16] A. Rowe,et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. , 2013, Chest.
[17] N. Thomson,et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. , 2013, The Journal of allergy and clinical immunology.
[18] C. Picado,et al. Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry , 2013, The Journal of asthma : official journal of the Association for the Care of Asthma.
[19] J. Fonseca,et al. Validation of Control of Allergic Rhinitis and Asthma Test for Children (CARATKids) – a prospective multicenter study , 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[20] N. Thomson,et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry , 2014, Thorax.
[21] O. Vandenplas,et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). , 2014, Respiratory medicine.
[22] P. Burton,et al. Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability , 2014, PloS one.
[23] J. Fonseca,et al. Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal. , 2015, Revista portuguesa de pneumologia.
[24] Are asthma patients willing to participate in an interactive web-based disease registry? , 2016 .
[25] D. Price,et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry , 2016, Thorax.
[26] N. Thomson,et al. Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. , 2016, Respiratory medicine.
[27] J. Soriano,et al. The ERS Research Agency: the beginning , 2016, European Respiratory Journal.
[28] Belgian Severe Asthma Registry. Which Biotherapy to Choose According to Inflammatory Characteristics , 2017 .
[29] Role and challenges of severe asthma services: insights from the UK registry. , 2017, Minerva medica.
[30] Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics , 2017, The Journal of asthma : official journal of the Association for the Care of Asthma.
[31] G. Canonica,et al. SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma , 2017, Clinical and Molecular Allergy.
[32] W. Busse,et al. Care pathways for the selection of a biologic in severe asthma , 2017, European Respiratory Journal.
[33] J. Drazen,et al. New Biologics for Asthma. , 2018, The New England journal of medicine.
[34] K. Samitas,et al. An algorithmic approach for the treatment of severe uncontrolled asthma , 2018, ERJ Open Research.